[Skip to Navigation]
December 5, 1959


Author Affiliations

Ohio State University Columbus 10, Ohio.

JAMA. 1959;171(14):1990. doi:10.1001/jama.1959.03010320080020

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:—  The matter of names of new drugs continues to raise problems. For commercial protection, it is necessary for a drug manufacturer to trademark a name for a new drug. Such a name is usually made as short and as easy to remember as possible in order to maintain commercial advantage through use of the trade name, even after patent rights to the drug itself may have expired. On the other hand, it is against the dignity, prestige, and best interests of scientists and members of the health professions to use trade names of drugs in scientific and professional communications. There is no point in scientists or professional men becoming advertising agents for commercial concerns. As a consequence, generic names which may be publicly used without any fear of involving the legal aspects of trade names must also be provided.In view of the increasing flamboyance of commercial

First Page Preview View Large
First page PDF preview
First page PDF preview